F-group (family)
2002.1.1.128 NAPRTase
Ligands and drugs
172
Member domains
146
with ligand contacts (≤ 4 Å)
84.9% of members
133
with DrugDomain annotations
77.3% of members
108
with a DrugBank compound
62.8% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 2002.1.1.128 belongs to X-group 2002 TIM beta/alpha-barrel, which binds 8.7 ligand superclasses per 20 proteins, broader than 71% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB02701 | NCA | Nicotinamide | 8 |
| DB12731 | DGB | Daporinad | 5 |
| DB00627 | NIO | Niacin | 2 |
| DB01119 | 20J | Diazoxide | 2 |
| DB02382 | NCN | Namn | 2 |
| DB03148 | A12 | Adenosine 5'-methylenediphosphate | 2 |
| DB03227 | NMN | Nicotinamide Mononucleotide | 2 |
| DB04160 | PPV | Pyrophosphoric acid | 2 |
| DB12980 | 2QG | CHS-828 | 2 |
| DB16761 | 2HJ | STF-31 | 2 |
| DB01632 | PRP | 5-O-phosphono-alpha-D-ribofuranosyl diphosphate | 1 |
| DB04447 | DTT | 1,4-Dithiothreitol | 1 |
| DB19243 | 96Q | Padnarsertib | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| CL | CHLORIDE ION | 19 |
| NCA | NICOTINAMIDE | 13 |
| DGB | (2E)-N-{4-[1-(benzenecarbonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)prop-2-enamide | 5 |
| MGmetal | MAGNESIUM ION | 5 |
| 1QS | N-{4-[(3,5-difluorophenyl)sulfonyl]benzyl}imidazo[1,2-a]pyridine-6-carboxamide | 4 |
| 2P1 | N-(4-{[3-(trifluoromethyl)phenyl]sulfonyl}benzyl)-2H-pyrazolo[3,4-b]pyridine-5-carboxamide | 4 |
| AMP | ADENOSINE MONOPHOSPHATE | 4 |
| J7F | 2-(2-~{tert}-butylphenoxy)-~{N}-(4-hydroxyphenyl)ethanamide | 4 |
| NMN | BETA-NICOTINAMIDE RIBOSE MONOPHOSPHATE | 4 |
| QCT | 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-deoxy-alpha-L-mannopyranoside | 4 |
| SJ6 | N-[[4-(6-methyl-1,3-benzoxazol-2-yl)phenyl]methyl]pyridine-3-carboxamide | 4 |
| 1XC | 6-({4-[(3,5-difluorophenyl)sulfonyl]benzyl}carbamoyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)imidazo[1,2-a]pyridin-1-ium | 3 |
| 7Z2 | N-[4-[(5R)-1-(4-azanylbutyl)-6-oxidanylidene-5-quinolin-5-yl-4,5-dihydropyridazin-3-yl]phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-2-carboxamide | 3 |
| BWA | N-{4-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-N'-[(pyridin-3-yl)methyl]urea | 3 |
| CVJ | (1S,2S)-N-{4-[(1S)-1-(propanoylamino)ethyl]phenyl}-2-(pyridin-3-yl)cyclopropane-1-carboxamide | 3 |
| CVP | 4-[(piperazin-1-yl)methyl]-N-{[4-({[(pyridin-3-yl)methyl]carbamoyl}amino)phenyl]methyl}benzamide | 3 |
| DPO | DIPHOSPHATE | 3 |
| NIO | NICOTINIC ACID | 3 |
| OE4 | N-{4-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-3-(pyridin-3-yl)azetidine-1-carboxamide | 3 |
| TK0 | (3S)-N-[(1-benzothiophen-5-yl)methyl]-1-[6-(4-{2-[(2E)-3-(pyridin-3-yl)prop-2-enamido]ethyl}phenyl)thieno[2,3-d]pyrimidin-4-yl]piperidine-3-carboxamide | 3 |